Atria Investments Inc Sells 19,174 Shares of Genmab A/S (NASDAQ:GMAB)

Atria Investments Inc cut its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 39.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,301 shares of the company's stock after selling 19,174 shares during the period. Atria Investments Inc's holdings in Genmab A/S were worth $612,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after acquiring an additional 827 shares during the period. GAMMA Investing LLC raised its holdings in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after acquiring an additional 1,051 shares during the period. Eagle Asset Management Inc. raised its holdings in shares of Genmab A/S by 10.0% during the third quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company's stock worth $285,000 after acquiring an additional 1,121 shares during the period. Grandfield & Dodd LLC raised its holdings in shares of Genmab A/S by 4.2% during the fourth quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company's stock worth $704,000 after acquiring an additional 1,370 shares during the period. Finally, Blue Trust Inc. raised its holdings in shares of Genmab A/S by 33.4% during the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock worth $120,000 after acquiring an additional 1,442 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Finally, Truist Financial lowered their price target on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of "Moderate Buy" and an average price target of $41.33.

Genmab A/S Stock Performance

Shares of GMAB stock traded down $0.60 during midday trading on Tuesday, hitting $20.20. 1,168,094 shares of the company were exchanged, compared to its average volume of 903,589. The firm has a market capitalization of $13.37 billion, a P/E ratio of 11.61, a PEG ratio of 2.65 and a beta of 0.98. The firm's 50 day moving average price is $21.22 and its two-hundred day moving average price is $22.33. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.02.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.